Humedix
Financials
Valuation Metrics
Humedix's Market Cap is ₩2447B. At end of 2025 it was ₩4457B. Ranked #698 of 2,410 in KR market (top 29%), #295 of 1,631 on KOSDAQ (top 18%), #73 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 32%) by Market Cap.
Investment Metrics(as of 2026-11-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 244.67B KRW | KR#698/2,410 Sec#73/231 |
| Revenue | 177.88B KRW | KR#1,093/2,410 Sec#65/231 |
| Net Income | 45.91B KRW | KR#444/2,410 Sec#27/231 |
| Total Assets | 323.64B KRW | KR#995/2,410 Sec#62/231 |
| Net Assets | 299.59B KRW | KR#718/2,410 Sec#47/231 |
| Employees | 371 | KR#649/2,410 Sec#57/231 |
| Value | ||
| P/E | 5.33x | KR#456/2,410 Sec#16/231 |
| P/B | 0.82x | KR#1,372/2,410 Sec#83/231 |
| PEG | 0.33x | KR#660/2,410 Sec#40/231 |
| P/S | 1.38x | KR#1,667/2,410 Sec#98/231 |
| EV/EBITDA | 5.03x | KR#284/2,410 Sec#6/231 |
| FCF Yield | 15.21% | KR#484/2,410 Sec#14/231 |
| Profitability | ||
| ROE | 15.32% | KR#310/2,410 Sec#19/231 |
| ROA | 14.19% | KR#132/2,410 Sec#10/231 |
| Op. Margin | 22.88% | KR#118/2,410 Sec#15/231 |
| Revenue Growth | 12.61% | KR#775/2,410 Sec#77/231 |
| Earnings Growth | 16.33% | KR#718/2,410 Sec#48/231 |
| Financial Health | ||
| Debt Ratio | 8.03% | KR#92/2,410 Sec#19/231 |
| Total Debt | 0 KRW | KR—/2,410 Sec—/231 |
| FCF | 37.21B KRW | KR#355/2,410 Sec#21/231 |
| Cash | 39.88B KRW | KR#854/2,410 Sec#53/231 |
| Net Debt/EBITDA | -0.98x | KR#388/2,410 Sec#21/231 |
| Dividend | ||
| Div. Yield | 4.14% | KR#472/2,410 Sec#17/231 |
| Div. Growth | 46.03% | KR#268/2,410 Sec#10/231 |
| Performance | ||
| 1Y Return | -56.40% | KR#2,078/2,410 Sec#191/231 |
| 1M Return | -13.81% | KR#1,180/2,410 Sec#118/231 |
| From 52W High | -57.97% | KR#1,493/2,410 Sec#123/231 |
| 1Y MDD | -56.99% | KR#1,239/2,410 Sec#101/231 |
| Trading | ||
| Volume | 13,697 shares | KR#1,661/2,410 Sec#171/231 |
| Trading Value | 303.0M KRW | KR#944/2,410 Sec#105/231 |
| Foreign Own. | 6.59% | KR#675/2,410 Sec#59/231 |
| Per Share | ||
| EPS | 4,156 KRW | KR#253/2,410 Sec#15/231 |
| BPS | 27,122 KRW | KR#414/2,410 Sec#30/231 |
Company Info
Humedix, established in 2003 for the manufacturing and sale of functional foods, changed its name from its original in 2010 and was listed on KOSDAQ in 2014. Through research and development of hyaluronic acid and PDRN, the company produces and supplies fillers, botulinum toxin, arthritis therapeutics, and cosmetics to domestic and international healthcare markets. Humedix strengthens its market presence by acquiring European CE and Chinese NMPA certifications for its proprietary HI method fillers. It maximizes synergy through heparin sodium localization and an aesthetic solution portfolio, and is headquartered in Seongnam-si, Gyeonggi-do.